Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer International Country of Publication: England NLM ID: 9100105 Publication Model: Print Cited Medium: Print ISSN: 0937-941X (Print) Linking ISSN: 0937941X NLM ISO Abbreviation: Osteoporos Int Subsets: MEDLINE
    • Publication Information:
      Original Publication: London, UK : Springer International, c1990-
    • Subject Terms:
      Hemostasis/*drug effects ; Hemostatics/*therapeutic use ; Osteoporosis/*drug therapy ; Vitamin K 2/*analogs & derivatives ; Vitamin K 2/*therapeutic use ; Vitamin K Deficiency/*blood; Aged ; Aged, 80 and over ; Blood Coagulation Factors/metabolism ; Cyanoacrylates/metabolism ; Female ; Hemostatics/blood ; Humans ; Male ; Osteoporosis/blood ; Osteoporosis/complications ; Osteoporosis, Postmenopausal/blood ; Osteoporosis, Postmenopausal/complications ; Osteoporosis, Postmenopausal/drug therapy ; Vitamin K 1/blood ; Vitamin K 2/blood ; Vitamin K Deficiency/complications
    • Abstract:
      The administration of menaquinone-4 (MK-4), one of subclasses of vitamin K2, significantly reduces bone loss in postmenopausal osteoporotic women. However, concerns have been raised about whether vitamin K administration alters the hemostatic balance by inducing a thrombotic tendency. We investigated were whether the administration of vitamin K in the form of MK-4 induced a thrombotic tendency in 29 elderly patients with osteoporosis (5 men, 24 women; age range 78.7+/-5.1 years). Patients were administered 45 mg/day (three times a day, 30 min after each meal) of MK-4 for 12 weeks. Blood samples were obtained from the patients at 0, 4 and 12 weeks after the start of MK-4 administration. A number of hemostatic parameters remained stable under the markedly increased plasma levels of MK-4. However, in patients with suspected vitamin K deficiency, whose plasma levels of vitamin K or factor VII were low, vitamin-K-dependent clotting factors such as factor VII and prothrombin were gradually increased after administration of MK-4. No changes in the sensitive molecular markers such as TAT and F1+2, which reflect the amount of thrombin generated in the blood stream, were observed, even in those patients with suspected vitamin K deficiency. These results indicate that MK-4 can be administered safely, with regard to maintaining the hemostatic balance, to osteoporotic patients receiving no anticoagulant therapy.
    • Accession Number:
      0 (Blood Coagulation Factors)
      0 (Cyanoacrylates)
      0 (Hemostatics)
      11032-49-8 (Vitamin K 2)
      25067-30-5 (cyacrin)
      27Y876D139 (menatetrenone)
      84-80-0 (Vitamin K 1)
    • Publication Date:
      Date Created: 20020216 Date Completed: 20020314 Latest Revision: 20121115
    • Publication Date:
      20240829
    • Accession Number:
      10.1007/s001980170007
    • Accession Number:
      11846334